GLP-1 receptor agonists for osteoarthritis: what does the evidence show?
BMC Musculoskeletal Disorders · 23 Oct 2026
† Impact is the editorial-priority score. All scores are out of 100. Clinical is a stored clinical-importance score from the earlier method; it has not been recalculated.
Why it matters
GLP-1 agonists are now widely prescribed for obesity, so students should know that they may ease knee osteoarthritis pain but have not been shown to prevent joint replacement.
The evidence
This systematic review pooled two randomised trials and five observational studies (160,089 patients in total) to ask whether GLP-1 receptor agonists such as semaglutide help overweight or obese adults with hip or knee osteoarthritis. The best evidence, one placebo-controlled trial, showed semaglutide improved WOMAC pain by 14.1 points more than placebo on a 0 to 100 scale. A second trial found no significant pain benefit after prior diet-induced weight loss. Observational studies linked the drugs to fewer hip and knee replacements (hazard ratios 0.60 and 0.75) and slightly slower cartilage loss, but certainty was low.
A coherent primary effect estimate is unavailable. Clinical relevance does not estimate treatment benefit.
Why this rigour score?
Meta-analysis (mixed designs)Design starting point: 42.6
Raised the score
- Placebo or sham control+5.1
- Prospectively registered+5.1
Lowered the score
- Pools mixed study designs−3.4
Methods at a glance
Recorded assessment- Comprehensive literature searchMet
- Risk of bias assessedMet
- Bias considered in synthesisMet
- Publication bias assessedNot met
- Study exclusions justifiedNot met
- Prospective registrationMet
Not reported does not mean not done. Checks have different weights; this is not a count of boxes ticked.
See the full score breakdown
- Study design starting point
- 42.6
- Placebo or sham control
- +5.1
- Prospectively registered
- +5.1
- Pools mixed study designs
- −3.4
- Comprehensive literature search
- +3.4
- Risk of bias assessed in the included studies
- +3.4
- Risk of bias carried into the synthesis
- +2.5
- Final rigour score rounded
- 59 / 100
Study design sets the starting point and a ceiling of 82. Recorded methods then adjust the score. Points are shown to one decimal place; the final score uses unrounded values.
Checklist from the stored appraisal. “Not met” describes the recorded criterion; it does not always produce a deduction. This overview supports reading the full study.
For journal club
1.For an obese patient with Kellgren-Lawrence grade 2 to 3 knee osteoarthritis who is not yet a surgical candidate, how would you counsel them on starting a GLP-1 agonist alongside exercise and other nonoperative care?
2.Should surgeons delay or reconsider referral for knee or hip arthroplasty in patients on GLP-1 agonists, given that observational data suggest lower conversion to arthroplasty but cannot rule out confounding?
Original publication title
Glucagon-like peptide-1 receptor agonists for osteoarthritis: a systematic review